Heterocyclic Compounds

Matches 451 - 500 out of 36,810	< 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 >

Document	Document Title
WO/2023/222122A1	SOLID FORMS OF A COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT Crystalline forms of Compound I, active on URAT1, were prepared and characterized: Also provided are methods of using the crystalline forms.
WO/2023/221900A1	SELECTIVE HER2 AND HER2 MUTATION INHIBITOR A selective HER2 inhibitor compound as shown in formula I or a pharmaceutically acceptable salt thereof.
WO/2023/223055A1	ANTI-VIRAL COMPOUNDS This invention relates to compounds that can be used to treat viral infections. The compounds of the present invention are papain-like protease (PLpro) inhibitors.
WO/2023/222084A1	BENZIMIDAZOLE OR AZABENZIMIDAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Disclosed in the present invention are a benzimidazole or azabenzimidazole compound, a preparation method therefor and a use thereof. The benzimidazole or azabenzimidazole compound has a structure shown in formula (I). A use of the compo...
WO/2023/225252A1	COMPOSITIONS AND METHODS FOR INHIBITION OF RAS Provided herein are compounds, or salts, esters, tautomers, prodrugs, zwitterionic forms, or stereoisomers thereof, as well as pharmaceutical compositions comprising the same. Also provided herein are methods of using the same in modulat...
WO/2023/009833A9	MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I), (II), or (III)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for ex...
WO/2023/224998A1	INHIBITORS OF PARG Provided herein are inhibitors of PARG, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the PARG inhibitory compounds for the treatment of disease.
WO/2023/224981A1	HSD17B13 INHIBITORS AND USES THEREOF Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...
WO/2023/221122A1	SALTS AND SOLID FORMS OF AN ESTROGEN RECEPTOR ANTAGONIST The present disclosure provides solid and salt forms of an estrogen receptor (ER) inhibitor, compositions thereof and methods of treating a ER-mediated disorder.
WO/2023/225244A1	HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE The present disclosure provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which lowering mutant huntingtin protein ("mHTT") in a subject is ...
WO/2023/224413A1	HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME, AND COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT-EMITTING ELEMENT The present specification provides a heterocyclic compound, an organic light-emitting element comprising same, and a composition for an organic layer of an organic light-emitting element.
WO/2023/223188A1	PROCESS FOR THE PREPARATION OF FINERENONE AND INTERMEDIATES THEREOF The present invention relates to a process for the preparation of finerenone, a compound of formula I, and intermediates thereof. In particular, the present invention relates to a novel diastereomeric salt of an intermediate of finerenon...
WO/2023/222850A1	AMIDO HETEROAROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF LIVER DISEASES The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the tr...
WO/2023/225001A1	NAPHTHYRIDINE BASED ENPP1 MODULATORS AND USES THEREOF The disclosure provides naphthyridines based on the ENPP1 modulators of Formula (I), (Ia), (Ib), (I-1), (I-1a), (I-1b), (I-2), (I-2a), (I-2b), or (Ic) and salts thereof, and their use for the modulation of ENPP1 activity.
WO/2023/217109A1	COMBINATION OF M6A RNA METHYLASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR FOR TREATING TUMORS A combination of a m6A RNA methylase inhibitor and an immune checkpoint inhibitor for treating tumors. The combination therapy is that the combination of a tumor immunotherapeutic agent and STM2457 or a derivative thereof is used for tre...
WO/2023/217230A1	KINESIN KIF18A INHIBITOR AND USE THEREOF The present invention provides a KIF18A inhibitor and a method for synthesizing same. The compound of the present invention can regulate KIF18A protein to influence the cell cycle and the cell proliferation process, so as to treat cancer...
WO/2023/220129A1	BENZOYPARAZINE PYRAZINES ANE THEIR USES The present disclosure features compounds of Formula I, Formula I, or pharmaceutically acceptable salts thereof, and formulations containing the same. Methods of treating BAF complex-related disorders, such as cancer, are also disclosed.
WO/2023/220238A1	LRRK2 INHIBITORS The present invention relates to imidazo[4,5-c]quinoline compounds of Formula (I), and pharmaceutically acceptable salts thereof. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and t...
WO/2023/217045A1	FLUOROQUINOXALINONE DERIVATIVE FOR SELECTIVELY INHIBITING PARP1 Disclosed is a series of fluorine-substituted heterocyclic compounds, and specifically, disclosed are a compound represented by formula (XII) and a pharmaceutically acceptable salt thereof.
WO/2023/220402A1	ENPP1 MODULATORS AND PRODUCTS AND USES THEREOF Disclosed herein are compounds having the structure of Formula (I): or a pharmaceutically acceptable salt, solvate, hydrate, isomer, tautomer, racemate, or isotope thereof, wherein A, Q1, R2, R3, Q4, R5, R6, R7, R and n are as defined he...
WO/2023/218195A1	GCN2 INHIBITORR The invention provides compounds of formula (I) Wherein the substituents are as set out in further detail in the specification. The compounds are potent inhibitors of GCN2 and they have excellent pharmacokinetic properties. The compounds...
WO/2023/218470A1	EFFICIENT PROCESS FOR PREPARATION OF APIXABAN HAVING CRYSTALLINE PARTICLES WITH D90 GREATER THAN 89 MICRON A cost-efficient process for the preparation of Apixaban of Formula I having crystalline particles size distribution D90 greater than 89 μm comprising insitu slow cooling crystallization without isolating crude making the said process o...
WO/2023/220640A1	CDK PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS Provided herein are CDK protein degraders, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CDK-me...
WO/2023/218201A1	IKK INHIBITORS The present invention relates to IKK-alpha inhibitory compounds, or a pharmaceutically acceptable salts, hydrates or solvates thereof, having the structural Formula (I), shown below: (I) wherein R1, X, R3 R4 and X1 are each as defined he...
WO/2023/217067A1	ENGINEERED IMMUNE EFFECTOR CELL AND USE THEREOF IN COMBINATION WITH CBL-B INHIBITOR The present application relates to an engineered immune effector cell and combined use thereof with and/or other active substances (such as the PDL1-IL15 fusion protein). The combined use relates to the preparation of a drug for treating...
WO/2023/220098A1	MENIN-MLL INHIBITORS FOR THE TREATMENT OF CANCER The present disclosure is directed to methods of treating colorectal cancer in a subject in need thereof with a menin-MLL inhibitor, including Compound A. Methods for dosing Compound A for various indications are also provided by the pre...
WO/2023/217906A1	PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE The present disclosure relates to compounds of Formula (I) that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are useful for preventin...
WO/2022/213204A9	CARBOXAMIDE PYROLOPYRAZINE AND PYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF MYT1 AND USE THEREOF IN THE TREATMENT OF CANCER The use of inhibitors of tyrosine and threonine- specific cdc2-inhibitory kinase (Mytl) in the treatment of cancer is disclosed. In preferred embodiments, the Mytl inhibitor is a carboxamide pyrrolopyrazine or carboxamide pyrrolopyridine...
WO/2023/220247A1	LRRK2 INHIBITORS The present invention relates to imidazo[4,5-c]quinoline compounds of Formula (I), and pharmaceutically acceptable salts thereof. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and t...
WO/2023/217201A2	NOVEL PYRIMIDO-HETEROCYCLIC NOVEL COMPOUND SERVING AS WEE1 INHIBITOR AND APPLICATION THEREOF Disclosed in the present invention is a novel pyrimido-heterocyclic compound having WEE1 target inhibitory activity, and specifically discloses a compound having a structure represented by formula (I) or a pharmaceutically acceptable sal...
WO/2023/218484A1	BICYCLIC COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS The present invention provides novel bicyclic compounds of formula (I), Formula (I) wherein, the definition of A1, A2, A3, A4, A5, Z, D, R3, R8 and R8a is described in the detailed description. which are demonstrating high pesticidal eff...
WO/2023/220219A1	COMPOUNDS AND USES THEREOF The present disclosure features compounds of Formula I, or pharmaceutically acceptable salts thereof, and formulations containing the same. Methods of treating BAF complex-related disorders, such as cancer, are also disclosed.
WO/2023/220049A1	CRYSTALLINE POLYMORPHS OF N-METHYL-N-((1S,3S)-3-METHYL-3-((6-(1-METHYL-1H-PYRAZOL-4-YL)PYRAZOLO[1,5-A]PYRA ZIN-4-YL)OXY)CYCLOBUTYL)ACRYLAMIDE Provided are crystalline forms of N-methyl-N-((ls,3s)-3-methyl-3-((6-(l-methyl-lH- pyrazol-4-yl)pyrazolo[l,5-a]pyrazin-4-yl)oxy)cyclobutyl)acry lamide, pharmaceutical compositions, methods of use and methods of making thereof.
WO/2023/220741A1	ALPHA 4 BETA 7 INTEGRIN MODULATORS AND USES THEREOF The present disclosure provides small molecule compounds and pharmaceutical compositions for the modulation of alpha 4 beta 7 integrin, useful for the treatment of inflammatory conditions such as inflammatory bowel disease, including ulc...
WO/2023/219941A1	8- AND 6-SUBSTITUTED PYRIDOPYRIMIDINE DERIVATIVES AS KRAS INHIBITORS The present invention is directed to inhibitors of Kirsten Rat sarcoma virus (KRAS), and more particularly to compounds of Formula (I), as well as compositions comprising Formula (I) and methods of using the compound of Formula (I) for t...
WO/2023/220046A1	TYK2 INHIBITORS This disclosure relates to compounds of formula (I), or pharmaceutically acceptable salts thereof: in which all of the variables are as defined in the application. The compounds of the present disclosure are capable of inhibiting the act...
WO/2023/216533A1	INDOLE ALKALOID, AND PREPARATION METHOD THEREFOR AND USE THEREOF The present invention relates to an indole alkaloid, and a preparation method therefor and the use thereof. Specifically disclosed in the present invention are a compound as shown in formula I and a preparation method therefor, and a pha...
WO/2023/216237A1	HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS, AND METHODS OF USE THEREOF Disclosed herein are compounds of Formula I, and/or stereoisomers, stable isotopes, or pharmaceutically acceptable salts or solvates thereof; and therapeutic uses of these compounds, which are inhibitors of rearranged during transfection...
WO/2023/215465A1	SUBSTITUTED IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES, AND USE OF SAME FOR TREATING, AMELIORATING, AND/OR PREVENTING RETINAL DEGENERATION The disclosure provides a method of treating, ameliorating, and/or preventing retinal degenerations, such as but not limited to anterior segment ocular disorders and/or age related macular degeneration (AMD), in a subject. In certain emb...
WO/2023/213271A1	HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH Provided herein are compounds having the following structure: or a pharmaceutically acceptable salt, tautomer, stereoisomer, or enantiomer thereof, wherein the substituents are as defined herein, compositions comprising an effective amou...
WO/2023/215802A1	HETEROCYCLIC COMPOUNDS AND USES THEREOF The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, ...
WO/2023/215238A1	PREPARATION AND USES OF 7-AZAINDENOISOQUINOLINES Described herein are new 8,9-dialoxy-7-azaindenoisoquinoline compounds (I), processes for their preparation, and methods of their use in the treatment of diseases responsive to inhibition of topoisomerase 1 and/or binding to the c-MYC G-...
WO/2023/213525A1	2-(5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-b]PYRIDIN-3-YL)-5-NITROSOPYRIMIDI N-4,6-DIAMINE OR A SALT THEREOF, METHOD FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE SYNTHESIS OF VERICIGUAT The invention is directed to a 2-(5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-y l)-5- nitrosopyrimidin-4,6-diamine, or a salt thereof, to a method for its preparation, to the use of said compound in the preparation of vericig...
WO/2023/213269A1	AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KRAS G12D MODULATORS AND USES THEREOF Disclosed are compounds of formula (I), which can be inhibitors of KRAS G12D, and their uses.
WO/2023/215367A1	BICYCLIC PIPERAZINONES AND THERAPEUTIC USES THEREOF Provided herein are compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein Z1, Z2, Z3, R1, R2, R3, and n are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a comp...
WO/2023/213739A1	NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS Compounds of general formula (I), pharmaceutical compositions comprising the compound, uses of the compositions, and methods of manufacturing the compound are disclosed. The compounds are nicotinic acetylcholine receptor (nAChR) ligands,...
WO/2023/213174A1	POLYMORPH OF CHLOROINDOLE HYDRAZIDE, PREPARATION METHOD THEREFOR AND FORMULATION PROCESSING TECHNOLOGY The present invention relates to a polymorph of chloroindole hydrazide, a preparation method therefor and a formulation processing technology, and belongs to the technical field of pesticides. The present invention provides a plurality o...
WO/2023/214404A1	A MUCOADHESIVE FILM COMPRISING A PHARMACEUTICALLY ACTIVE AGENT AND USES THEREOF A mucoadhesive composition and method for the administration of the pharmaceutically effective agents is provided. Specifically, a mucoadhesive composition, composed of a mucoadhesive polymer and a plurality of active agents having diffe...
WO/2023/215801A1	HETEROCYCLIC COMPOUNDS AND USES THEREOF The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same in the treatment of cancer or for inhibiting cell growth. The compounds and methods have a range of utilities as thera...
WO/2023/213836A1	SULFONAMIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS The present invention discloses compounds according to Formula (I) wherein R1, R2a, R2b, R3, X, Y, and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compos...

Matches 451 - 500 out of 36,810	< 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 >